Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
		Sep. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Available-for-sale Securities, Total			$ 20,000	$ 87,800
Debt Securities, Available-for-sale, Total			12,500	36,400
Finite-lived Intangible Assets Acquired			153,311	0
Amortization of Intangible Assets, Total			64,940	61,095
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	[1]		4,000	0	$ 0
Patented Technology [Member]
Finite-lived Intangible Assets Acquired		$ 5,000
Noncash or Part Noncash Acquisition, Intangible Assets Acquired			4,000
Developed Technology Rights [Member] | Cost of Sales [Member]
Amortization of Intangible Assets, Total			36,500	34,500	33,300
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]
Amortization of Intangible Assets, Total			28,400	26,600	$ 25,400
Other Noncurrent Assets [Member]
Inventory, Finished Goods, Net of Reserves, Non-current			5,456	4,646
ChemoCentryx, Inc (CCXI) [Member]
Available-for-sale Equity Securities, Amortized Cost Basis, Total			$ 6,600	$ 6,600
ChemoCentryx, Inc (CCXI) [Member]
Share Price (in dollars per share)			$ 13.39	$ 57.54

[1] $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.